School of Chemical and Life Sciences, Biomedical Science Section, Singapore Polytechnic, 500 Dover Road, Singapore.
Virus Res. 2010 Jun;150(1-2):85-92. doi: 10.1016/j.virusres.2010.02.017. Epub 2010 Mar 7.
Coxsackievirus B4 (CVB4) can cause a broad range of diseases such as aseptic meningitis, meningoencephalitis, myocarditis, hepatitis, pancreatitis, gastroenteritis, necrotizing enterocolitis, pneumonia and sudden death in the neonates. CVB4 has also been implicated as a possible etiological agent for type 1 insulin dependent diabetes mellitus (IDDM). In this study, the possibility of RNA interference (RNAi) as a potential therapeutic approach to treat CVB4 infection was explored. The results showed that the Rhabdomyosarcoma (RD) cells treated with 19-mer siRNAs displayed high specificity against CVB4 replication without displaying any sign of target effects. The siRNA targeting the 3C(pro) region of CVB4 genome was also established to be the most effective in inhibition of CVB4 replication in RD cell line in a dosage dependent manner, indicating its potential to be developed as an antiviral strategy against CVB4.
柯萨奇病毒 B4（CVB4）可引起广泛的疾病，如无菌性脑膜炎、脑膜脑炎、心肌炎、肝炎、胰腺炎、胃肠炎、坏死性小肠结肠炎、肺炎和新生儿猝死。CVB4 也被认为是 1 型胰岛素依赖型糖尿病（IDDM）的可能病因。在这项研究中，探讨了 RNA 干扰（RNAi）作为治疗 CVB4 感染的潜在治疗方法的可能性。结果表明，用 19 个核苷酸 siRNA 处理的横纹肌肉瘤（RD）细胞对 CVB4 复制具有高度特异性，而没有显示出任何靶效应的迹象。针对 CVB4 基因组 3C(pro) 区域的 siRNA 也被证明在剂量依赖性方式下最有效地抑制 RD 细胞系中的 CVB4 复制，表明其具有作为针对 CVB4 的抗病毒策略的开发潜力。
